267 results on '"Tölg, Ralph"'
Search Results
2. Design and Rationale of the BIOFLOW-DAPT Trial: a Prospective, Randomized, Multicenter Study to Assess the Safety of the Orsiro Mission Stent Compared to the Resolute Onyx Stent in Subjects at High Risk for Bleeding in Combination with 1-Month Dual Antiplatelet Therapy
3. One-Month Versus Three-Month Dual-Antiplatelet Therapy in High Bleeding Risk Patients With Chronic Kidney Disease
4. In-hospital Outcomes of Rotational Atherectomy in ST-Elevation Myocardial Infarction: Results From the Multicentre ROTA-STEMI Network
5. 1- Versus 3-Month DAPT in Older Patients at a High Bleeding Risk Undergoing PCI: Insights from the XIENCE Short DAPT Global Program
6. Bleeding and Ischemic Risk Prediction in Patients With High Bleeding Risk (an EVOLVE Short DAPT Analysis)
7. Design and rationale of a prospective, randomized, non-inferiority trial to determine the safety and efficacy of the Biolimus A9™ drug coated balloon for the treatment of in-stent restenosis: First-in-man trial (REFORM)
8. 1- or 3-Month DAPT in Patients With HBR With or Without Oral Anticoagulant Therapy After PCI
9. Safety and performance of the third-generation drug-eluting resorbable coronary magnesium scaffold system in the treatment of subjects with de novo coronary artery lesions: 6-month results of the prospective, multicenter BIOMAG-I first-in-human study
10. Ablation of typical atrial flutter as therapeutic component in carcinoid heart disease: a case report
11. Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI
12. Sustained Safety and Performance of the Second-Generation Sirolimus-Eluting Absorbable Metal Scaffold: Pooled Outcomes of the BIOSOLVE-II and -III Trials at 3 Years
13. Predictors of In-Hospital Adverse Outcomes after Rotational Atherectomy: Impact of the Target Vessel SYNTAX Score
14. 5-Year Outcomes After TAVR With Balloon-Expandable Versus Self-Expanding Valves: Results From the CHOICE Randomized Clinical Trial
15. Transcatheter Aortic Valve Implantation With the Third Generation Balloon-Expandable Bioprosthesis in Patients With Severe Landing Zone Calcium
16. Association between duration of drug-coated balloon inflation and efficacy in patients with drug-eluting stent restenosis
17. Anschriften der Herausgeber und Autoren
18. Impact of Revascularization Completeness on Outcomes of Patients with Coronary Artery Disease Undergoing Transcatheter Aortic Valve Replacement
19. First Report of Edge Vascular Response at 12 Months of Magmaris, A Second-Generation Drug-Eluting Resorbable Magnesium Scaffold, Assessed by Grayscale Intravascular Ultrasound, Virtual Histology, and Optical Coherence Tomography. A Biosolve-II Trial Sub-Study
20. Serial 3-Dimensional Optical Coherence Tomography Assessment of Jailed Side-Branch by Second-Generation Drug-Eluting Absorbable Metal Scaffold (from the BIOSOLVE-II Trial)
21. Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial
22. In vivo serial invasive imaging of the second-generation drug-eluting absorbable metal scaffold (Magmaris — DREAMS 2G) in de novo coronary lesions: Insights from the BIOSOLVE-II First-In-Man Trial
23. Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents: A Randomized Controlled Trial
24. ISCHEMIC RISK MATTERS - RISK STRATIFICATION IN HIGH BLEEDING RISK (HBR) PATIENTS IMPLANTED WITH THE SYNERGY STENT: A POST-HOC ANALYSIS OF THE EVOLVE SHORT DAPT STUDY
25. Clinical safety and efficacy of new-generation single-layer polytetrafluorethylene covered coronary stents
26. Incidence, feasibility and outcome of percutaneous coronary intervention after transcatheter aortic valve implantation with a self-expanding prosthesis. Results from a single center experience
27. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial
28. Optical Coherence Tomography Characteristics of the Novel Resorbable Magnesium Scaffold at 6 Months: An Intravascular Imaging Analysis of the First-in-Human Trial on DREAMS 3G
29. Are There Coronary Plaque Characteristics Associated With Late Lumen Loss? Artificial Intelligence-Based Optical Coherence Tomography (OCT) Study From the First-in-Human Trial on DREAMS 3G Scaffold
30. Anschriften der Herausgeber und Autoren
31. High-speed rotational atherectomy of the left main coronary artery: a single-center experience in 50 high-risk patients
32. Effect of strut distribution on neointimal coverage of everolimus-eluting bioresorbable scaffolds: an optical coherence tomography study
33. Neointimal response to everolimus-eluting bioresorbable scaffolds implanted at bifurcating coronary segments: insights from optical coherence tomography
34. Predictors of acute scaffold recoil after implantation of the everolimus-eluting bioresorbable scaffold: an optical coherence tomography assessment in native coronary arteries
35. Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials
36. Clinical Outcomes of the Resolute Zotarolimus-Eluting Stent in Patients With In-Stent Restenosis: 2-Year Results From a Pooled Analysis
37. High-Speed Rotational Atherectomy Before Paclitaxel-Eluting Stent Implantation in Complex Calcified Coronary Lesions: The Randomized ROTAXUS (Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease) Trial
38. Twelve-month results of a Paclitaxel Releasing Balloon in Patients Presenting with In-stent Restenosis First-in-Man (PEPPER) trial
39. Comparison of Outcomes in Patients Having Isolated Transcatheter Aortic Valve Implantation Versus Combined With Preprocedural Percutaneous Coronary Intervention
40. No Evidence of “Obesity Paradox” After Treatment With Drug-Eluting Stents in a Routine Clinical Practice: Results From the Prospective Multicenter German DES.DE (German Drug-Eluting Stent) Registry
41. Comparison of Hospital Mortality With Intra-Aortic Balloon Counterpulsation Insertion Before Versus After Primary Percutaneous Coronary Intervention for Cardiogenic Shock Complicating Acute Myocardial Infarction
42. Early hemodynamic and neurohormonal response after transcatheter aortic valve implantation
43. Impact of Endothelial Shear Stress on Absorption Process of Resorbable Magnesium Scaffold: A BIOSOLVE-II Substudy
44. TCT-356 Patients With Moderate to Severe Lesion Tortuosity Undergoing Coronary Intervention With Newer-Generation Drug Eluting Stents: An Analysis From the Randomized BIOFLOW Trials
45. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting
46. Outcome of percutaneous coronary intervention with drug-eluting stents in unprotected left main versus non-left main native coronary artery disease: results from the prospective multicenter German DES.DE registry
47. Association between duration of drug-coated balloon inflation and efficacy in patients with drug-eluting stent restenosis
48. Cardiogoniometry as a diagnostic tool in patients with acute coronary syndromes: results of the CGM@ACS trial
49. Prognostic Value of the Modified American College of Cardiology/American Heart Association Lesion Morphology Classification for Clinical Outcome After Sirolimus-Eluting Stent Placement (Results of the Prospective Multicenter German Cypher Registry)
50. Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.